Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia

  • Leigh DelbridgeEmail author
Part of the Current Clinical Oncology book series (CCO)


Thyroid cancer arises from follicular cells, giving rise to several types of cancer (papillary, follicular, Hurthle cell, and anaplastic thyroid cancer); C-cells, giving rise to medullary cancer; or lymphocytes and stromal cells, giving rise to thyroid lymphoma or sarcoma. This counterpoint will summarize the Australian practice of surveillance for patients with well-differentiated thyroid cancer of follicular cell origin and medullary thyroid cancer treated surgically with curative intent.


Papillary thyroid cancer Follicular thyroid cancer Hurthle-cell thyroid cancer Medullary thyroid cancer Thyroidectomy Cervical lymph node dissection Serum thyroglobulin Thyroid autoantibodies Serum calcitonin Radioiodine ablative therapy 


  1. 1.
    Greene F, Page D, Fleming I, et al. Thyroid tumors. In: Greene F, Page D, Fleming I, et al., editors. AJCC cancer staging manual. New York: Springer; 2002. p. 77–87.Google Scholar
  2. 2.
    Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer (American Thyroid Association). Thyroid. 2006;16:109–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Shah MD, Hall FT, Eski SJ, Witterick IJ, Walfish PG, Freeman JL. Clinical course of thyroid carcinoma after neck dissection. Laryngoscope. 2003;113:2102–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery. 2006;140:1000–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Schlumberger M, Ricard M, De Pouvourville G, Pacini F. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer. Nat Clin Pract Endocrinol Metab. 2007;3:641–50.PubMedCrossRefGoogle Scholar
  6. 6.
    Roman S, Mehta P, Sosa JA. Medullary thyroid cancer: early detection and novel treatments. Curr Opin Oncol. 2009;21:5–10.PubMedCrossRefGoogle Scholar
  7. 7.
    Stavrou E, Baker D, McElroy H, Bishop J. Thyroid cancer in NSW. NSW Cancer Institute. Sydney, Australia: NSW Cancer Institute; 2008. p. 9–10.Google Scholar
  8. 8.
    Grodski S, Brown T, Sidhu S, Gill A, Robinson B, Learoyd D, Sywak M, Reeve T, Delbridge L. Increasing incidence of thyroid cancer is due to increased pathologic detection. Surgery. 2008;144:1038–43.PubMedCrossRefGoogle Scholar
  9. 9.
    Perros P, Clarke SE, Franklyn J, et al. Guidelines for the management of thyroid cancer (British Thyroid Association). 2nd ed. Suffolk: Lavenham Press, Royal College of Physicians of London; 2007.Google Scholar
  10. 10.
    Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery. 1998;124:958–64.PubMedCrossRefGoogle Scholar
  11. 11.
    Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report on the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid cancer. J Clin Endocrinol Metab. 2003;88:1433–41.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee L, Steward DL. Sonographically-directed neck dissection for recurrent thyroid carcinoma. Laryngoscope. 2008;118:991–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patents with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.PubMedCrossRefGoogle Scholar
  14. 14.
    Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004;150:105–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Pacini F, Capezzone M, Elisei R, et al. Diagnostic 131-iodine whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum thyroglobulin after initial treatment. J Clin Endocrinol Metab. 2002;87:1499–501.PubMedCrossRefGoogle Scholar
  16. 16.
    Pacini F, Molinaro E, Castagna MG. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:3668–73.PubMedCrossRefGoogle Scholar
  17. 17.
    David A, Blotta A, Rossi R, et al. Clinical value of different responses of serum thyroglobulin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid. 2005;15:267–73.PubMedCrossRefGoogle Scholar
  18. 18.
    Spencer CA. Challenges of serum thyroglobulin (thyroglobulin) measurement in the presence of thyroglobulin autoantibodies. J Clin Endocrinol Metab. 2004;89:3702–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Baudin E, Do Czao C, Cailleux AF, et al. Positive predictive value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88: 1107–11.PubMedCrossRefGoogle Scholar
  20. 20.
    McGriff NJ, Csako G, Gourgiotos L, Lori CG, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med. 2002;34:554–64.PubMedCrossRefGoogle Scholar
  21. 21.
    Machens A, Schneyer U, Holzhausen H, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005;90:2029–34.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press 2013

Authors and Affiliations

  1. 1.University of Sydney Endocrine Surgical UnitSydneyAustralia
  2. 2.Department of Endocrine and Oncology SurgeryRoyal North Shore HospitalSydneyAustralia

Personalised recommendations